Terrie Curran - 14 Jul 2023 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role: President and Chief Executive, Director
Signature: /s/ Larry Miller, Attorney-in-Fact for Terrie Curran
Issuer symbol: PHAT
Transactions as of: 14 Jul 2023
Net transactions value: $0
Form type: 4
Filing time: 17 Jul 2023, 17:00:14 UTC
Previous filing: 02 Jun 2023
Next filing: 03 Nov 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PHAT	Common Stock	Award		+200,000	+105%		389,671	14 Jul 2023	Direct	F1, F2
holding	PHAT	Common Stock						3,580	14 Jul 2023	by 401(k)	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PHAT	Stock Option	Disposed to Issuer		-175,000	-100%		0	14 Jul 2023	Common Stock	175,000	$32.20	Direct	F1
transaction	PHAT	Stock Option	Disposed to Issuer		-225,000	-100%		0	14 Jul 2023	Common Stock	225,000	$39.11	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 400,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 200,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock.
F2	Includes 1,381 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2023.
F3	Includes 1,223.71 shares acquired under the Phathom Pharmaceuticals, Inc. 401(k) plan.